FDA nixes EUA for Lilly’s bamlanivimab

FDA取消礼来公司的bamlanivimab的EUA

2021-04-20 11:30:06 Mass Device

本文共204个字,阅读需1分钟

On April 16, Lilly announced that it was requesting FDA to revoke the emergency use authorization (EUA) for the monoclonal antibody bamlanivimab (LY-CoV555) when used alone. Hours after, the agency agreed to rescind the EUA on the grounds that bamlanivimab is potentially ineffective against some SARS-CoV-2 variants. Bamlanivimab, however, won’t be disappearing as a COVID-19 treatment but will be paired with another monoclonal antibody known as etesevimab. Get the full story from our sister site, Drug Discovery & Development.
4月16日,礼来宣布正在请求FDA撤销单克隆抗体bamlanivimab(LY-CoV555)单独使用时的紧急使用授权(EUA)。 几小时后,该机构同意撤销EUA,理由是bamlanivimab对某些新型冠状病毒变体可能无效。 然而,Bamlanivimab作为COVID-19治疗药物不会消失,而是将与另一种名为eteseviMab的单克隆抗体配对使用。 从我们的姊妹网站,药物发现和发展获得完整的故事。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文